Cerenome Reported Q3 Billings of $1.55 Million
The Houston-based diagnostics firm recorded gross billings for 222 CNSide tests during the third quarter of 2026.
Updated on Sept. 30, 2026 in Economic Indicators
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?
Cerenome announced that it generated $1.55 million in unaudited gross billings for its CNSide testing platform during the third quarter of 2026. The performance reflects charges submitted for 222 tests to payers at list prices.
Why it matters
This billing milestone provides insight into the commercial adoption of the CNSide testing platform as the company prepares for an expanded reach in 2027. A favorable preliminary CMS pricing decision for code 0640U further supports the company's financial and coverage growth strategy.
Cerenome reported 222 tests billed in Q3 2026 across a base of 158 million contracted covered lives. The firm is currently tracking toward an annualized gross billing run rate of $10 million to $12 million for the fourth quarter.
The players
Cerenome
Cerenome is a Houston-based diagnostic company that develops and markets the CNSide testing platform for medical professionals.
The details
The billing figures are based on management reviews of claims submitted through September 30, 2026. Cerenome intends to bolster its market position in the fourth quarter by launching the CSF Molecular Profile Test and new breast cancer protein expression assays.
Timeline
Q3 2026 marked the period for the 222 tests billed totaling $1.55 million.
Q4 2026 is the target timeframe for the launch of the new CNSide testing menu.
January 1, 2027, is the target effective date for the CMS Medicare pricing decision.
Early 2027 is the goal for reaching 200 million covered lives and beneficiaries.
Macro View
The firm is aligning its growth with the regulatory framework governing the CMS Medicare pricing decision process for code 0640U. This approach mirrors standard industry efforts to secure consistent reimbursement structures to support long-term scalability.
The expansion of covered lives to a target of 200 million may improve diagnostic access for patients covered by participating insurance plans. These financial developments help stabilize the availability of specialized molecular testing for individuals in the healthcare system.
The takeaway
Cerenome is aggressively scaling its diagnostic operations through both new product launches and expanded insurance coverage. Investors and healthcare providers should monitor the transition toward the target 200 million covered lives as a key indicator of market penetration.
What happens next
Cerenome anticipates a CMS Medicare pricing decision to take effect on January 1, 2027.
Further reading
For broader trends on business growth metrics, see Economic Indicators.
More information
For more technical details on the testing technology, visit the CNSide diagnostic platform information.
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?
